Results 61 to 70 of about 10,799 (115)

Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity

Radiation Oncology, 2017
Objective To report grade ≥2 overall late rectal and urinary toxicities in patients (pts) with prostate cancer treated by intensity-modulated radiotherapy (IMRT) at 3 dose-levels.
Maria Jolnerovski, Julia Salleron, Véronique Beckendorf, Didier Peiffert, Anne-Sophie Baumann, Valérie Bernier, Sandrine Huger, Vincent Marchesi, Ciprian Chira   +8 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Circulating DNA reveals nucleosome occupancy patterns that are associated with nucleosome-DNA affinity and are affected in cancer

Genome Medicine
Background The study of cell-free circulating DNA (cirDNA) fragments (fragmentomics) from liquid biopsies has received increasing attention to detect biomarkers.
Marianne Richaud, Ekaterina Pisareva, Paul Burgat, Alain R. Thierry, Jacques Colinge   +4 more
doaj   +1 more source

13-year survival oligometastatic Merkel cell carcinoma: a case report

Journal of Medical Case Reports
Background Merkel cell carcinomas are rare, aggressive skin tumors with high metastatic potential and poor prognosis. Their treatment is classically based on surgery with adjuvant external radiotherapy for localized tumors or on immunotherapy or ...
I. Trampetti, J. C. Faivre, L. Geoffrois, W. Gehin, S. Renard   +4 more
doaj   +1 more source

The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST

Acta Oncologica
Background and purpose: In this manuscript we describe the academic French multicentric molecular analysis platforms including PROFILER, promoted by Centre Léon Berard, and the multicentric personalized medicine trials MOST, MOST Plus and MEGAMOST ...
Loic Verlingue, Marine Desevre, Marie Polito, Gwenaelle Garin, Christine Rodriguez, Wang Qing, Olivier Tredan, David Perol, Isabelle Ray-Coquard, Sylvie Chabaud, Jean Yves Blay   +10 more
doaj   +1 more source

Favourable long-term outcomes in selected HER2-Positive early breast cancer patients without pathological complete response after neoadjuvant chemotherapy and trastuzumab: A pre–T-DM1 era cohort study

Cancer Treatment and Research Communications
Background: Adjuvant trastuzumab emtansine (T-DM1) is the standard treatment for HER2-positive early breast cancer (EBC) patients who do not achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). Given the heterogeneity within
Ludovic Doucet, Camille Moreau-Bachelard, Laurent Mathiot, Olivier Kerdraon, Marie Robert, Julie Quintin, François Bocquet, Morgan Zenatri, Mario Campone, Jean-Sébastien Frenel   +9 more
doaj   +1 more source

EMT or EMT-promoting transcription factors, where to focus the light?

Frontiers in Oncology, 2014
Stéphane eAnsieau, Stéphane eAnsieau, Stéphane eAnsieau, Stéphane eAnsieau, Stéphane eAnsieau, Guillaume eCollin, Guillaume eCollin, Guillaume eCollin, Guillaume eCollin, Guillaume eCollin, Louise eHill, Louise eHill, Louise eHill, Louise eHill, Louise eHill   +14 more
doaj   +1 more source

Intraoperative Ex Vivo Confocal Microscopy for Surgical Margin Assessment in Squamous Cell and Basal Cell Carcinoma (HISTOBLOC): Protocol for a Prospective Monocentric Pilot Study. [PDF]

JMIR Res Protoc
Gravante G, Leroux A, Garbar C, Henry L, Cortese S, Beulque E, Mastronicola R, Dolivet G.   +7 more
europepmc   +1 more source

Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France. [PDF]

Breast
Frenel J, de Nonnevile A, Guerin-Charbonnel C, Zeghondy J, Mathiot L, Mailliez A, Poumeaud F, Isambert N, Arnedos M, Le Du F, Galland L, Kabirian R, Guiu S, Poestch L, Deluche E, Cherifi F, Dalenc F, Volant E, Pistilli B, San T, Bachelot T, Patsouris A, Bocquet F, Bailleux C, Loirat D, Larrouquere L.   +25 more
europepmc   +1 more source

Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction. [PDF]

J Bone Oncol
Massy E, Stacoffe N, Fauvernier M, Duruisseaux M, Grolleau E, Lamkhioued M, Pérol M, Domblides C, Roche M, Stuani A, Clézardin P, Bonnelye E, Pialat JB, Girard N, Confavreux C.   +14 more
europepmc   +1 more source